These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25592234)

  • 1. Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma.
    Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
    Cancer Epidemiol; 2015 Apr; 39(2):182-8. PubMed ID: 25592234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
    Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
    BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
    Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
    Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
    Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translesion polymerase genes polymorphisms and haplotypes influence survival of osteosarcoma patients.
    Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
    OMICS; 2015 Mar; 19(3):180-5. PubMed ID: 25748439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.
    Funke S; Timofeeva M; Risch A; Hoffmeister M; Stegmaier C; Seiler CM; Brenner H; Chang-Claude J
    Pharmacogenomics; 2010 Jan; 11(1):33-41. PubMed ID: 20017670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.
    Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
    Pharmacogenet Genomics; 2014 Oct; 24(10):514-21. PubMed ID: 25098908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
    Ji WP; He NB
    Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma.
    Wang MJ; Zhu Y; Guo XJ; Tian ZZ
    Genet Mol Res; 2015 Sep; 14(3):11652-7. PubMed ID: 26436406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients.
    Sreeja L; Syamala V; Hariharan S; Syamala VS; Raveendran PB; Sivanandan CD; Madhavan J; Ankathil R
    J Exp Ther Oncol; 2008; 7(1):73-85. PubMed ID: 18472644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
    Yang LM; Li XH; Bao CF
    Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin.
    Kap EJ; Richter S; Rudolph A; Jansen L; Ulrich A; Hoffmeister M; Ulrich CM; Brenner H; Chang-Claude J
    Pharmacogenet Genomics; 2014 Jul; 24(7):340-7. PubMed ID: 24842074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy.
    Mahimkar MB; Samant TA; Kannan S; Tulsulkar J; Pai PS; Anantharaman D
    Mol Carcinog; 2012 Oct; 51 Suppl 1():E94-103. PubMed ID: 22213390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
    Goekkurt E; Hoehn S; Wolschke C; Wittmer C; Stueber C; Hossfeld DK; Stoehlmacher J
    Br J Cancer; 2006 Jan; 94(2):281-6. PubMed ID: 16317430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.
    Beeghly A; Katsaros D; Chen H; Fracchioli S; Zhang Y; Massobrio M; Risch H; Jones B; Yu H
    Gynecol Oncol; 2006 Feb; 100(2):330-7. PubMed ID: 16199080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.
    Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
    Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
    Oldenburg J; Kraggerud SM; Cvancarova M; Lothe RA; Fossa SD
    J Clin Oncol; 2007 Feb; 25(6):708-14. PubMed ID: 17228018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
    Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
    Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome.
    Medeiros R; Pereira D; Afonso N; Palmeira C; Faleiro C; Afonso-Lopes C; Freitas-Silva M; Vasconcelos A; Costa S; Osório T; Lopes C
    Int J Clin Oncol; 2003 Jun; 8(3):156-61. PubMed ID: 12851839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.